Anavex Life Sciences Corp.
AVXL · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $759,076 | $474,098 | $522,611 | $793,711 |
| - Cash | $102,577 | $132,187 | $151,024 | $149,158 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $656,499 | $341,911 | $371,587 | $644,553 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | $5,293 | -$55,756 | -$50,942 |
| % Margin | – | – | – | – |
| Net Income | $0 | -$43,002 | -$47,505 | -$47,978 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.54 | -0.52 | -0.6 | -0.62 |
| % Growth | -3.8% | 13.3% | 3.2% | – |
| Operating Cash Flow | -$39,044 | -$30,812 | -$27,785 | -$24,238 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$39,044 | -$30,812 | -$27,785 | -$24,238 |